...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
【24h】

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors

机译：钠-葡萄糖共转运蛋白2抑制剂的血流动力学效应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It is widely accepted that obesity and type 2 diabetes mellitus (T2DM) increase the risk of heart failure (HF) independently of underlying coronary artery disease. The changes in myocardial structure or function associated with diabetes have been termed diabetic cardiomyopathy. Corresponding to changes in the risk factors for HF, an epidemiologic transition is underway from HF with a reduced ejection fraction to HF with a preserved ejection fraction. Hyperglycemia can damage the myocardium, even before diagnosis of diabetes, but intensive glycemic control has no impact on the risk of HF in patients with T2DM. Recent clinical studies have demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitors, which inhibit renal reabsorption of glucose, decrease the risk of HF in T2DM patients. The cardioprotective mechanisms involved appear to be multifactorial and have been the subject of considerable debate. This review focuses on the hemodynamic effects of SGLT2 inhibitors in T2DM patients and the mechanisms by which these drugs decrease the risk of HF.J Clin Med Res. 2017;9(6):457-460doi: https://doi.org/10.14740/jocmr3011w
机译：肥胖和2型糖尿病（T2DM）会独立于潜在的冠状动脉疾病而增加心力衰竭（HF）的风险，这一点已被广泛接受。与糖尿病有关的心肌结构或功能的改变被称为糖尿病性心肌病。与HF危险因素的变化相对应，流行病学正在从射血分数降低的HF向射血分数保留的HF过渡。高血糖症甚至可以在诊断为糖尿病之前就损害心肌，但严格的血糖控制对2型糖尿病患者的HF风险没有影响。最近的临床研究表明，抑制肾脏对葡萄糖的重吸收的钠葡萄糖共转运蛋白2（SGLT2）抑制剂可降低T2DM患者的HF风险。涉及的心脏保护机制似乎是多因素的，并且已经引起了广泛的争论。这篇综述着重于SGLT2抑制剂在T2DM患者中的血液动力学作用以及这些药物降低HF风险的机制。JClin Med Res。 2017; 9（6）：457-460doi：https://doi.org/10.14740/jocmr3011w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号